Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest

NEW YORK; Feb. 2, 2023 – Accenture (NYSE: ACN) has acquired Bionest, a strategy and consulting firm dedicated to addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy (CGT), and rare diseases.
February 02, 2023

Digital Health Reshaping MedTech Industry as Consumers Demand “Anywhere, Everywhere” Healthcare, Accenture and AdvaMed Report Finds

NEW YORK; Nov. 9, 2022 – The medical technology (MedTech) industry is being reshaped by digital health and consumers' expectations to receive care how, when and where they want, according to a new report from Accenture (NYSE: ACN) and AdvaMed.
November 09, 2022

Emerging Technologies Ushering the Life Sciences Industry into the Metaverse, according to Accenture Report

NEW YORK; Aug. 22, 2022 – Accenture’s (NYSE: ACN) Life Sciences Technology Vision 2022 report explores the technology trends that will transform how biopharmaceutical and medical technology companies solve manufacturing and device problems, improve equity in clinical trial participation and build more resilient supply chains to provide patients and healthcare professionals with more personalized experiences.
August 22, 2022

Most Companies Struggling to be Relevant to Their Customers, Accenture Report Finds

NEW YORK; July 26, 2022 – The vast majority (88%) of executives1 believe that customers and employees are changing faster than they can change their businesses, which is leading to a crisis of relevance, according to a new report from Accenture (NYSE: ACN).  
July 26, 2022

Accenture Accelerates Data-Driven Decision Making for Lupin

NEW DELHI, India; June 20, 2022 – Lupin Limited (Lupin), a global pharmaceutical company has collaborated with Accenture (NYSE: ACN) to enable its data driven transformation journey for improved business agility, performance, and operational efficiency.
June 20, 2022

Accenture Named a Leader in Healthcare Payer Digital Services PEAK Matrix® Assessment by Everest Group

NEW YORK; June 2, 2022 – Accenture (NYSE: ACN) has been named a Leader in the healthcare payer digital services provider landscape in a recent report from Everest Group.
June 02, 2022

IDC MarketScape Positions Accenture a Leader in Life Science Sales and Marketing IT Outsourcing Services

NEW YORK; April 28, 2022 – Accenture (NYSE: ACN) is positioned as a leader in the IDC MarketScape analysis of life science sales and marketing IT outsourcing services in 2022.
April 28, 2022

Accenture Joins AI4BetterHearts Data Collaborative

NEW YORK; March 29, 2022 – Accenture (NYSE: ACN) has joined AI4BetterHearts, a global data collaborative founded by Microsoft and the Novartis Foundation, that aims to help stakeholders —
from policy makers to patients — make better decisions about heart health and improve the health of entire populations.
March 29, 2022

Nine Out of Ten Healthcare Executives Say That Health Equity Initiatives are a Top Business Priority, According to Accenture and HIMSS Insights

NEW YORK; March 15, 2022 – New research from Accenture (NYSE: ACN) and HIMSS Market Insights reveals that 93% of U.S. healthcare executives believe that health equity initiatives are important and 89% agree that such initiatives are part of their core business strategy. However, only slightly more than a third (36%) have a specific budget dedicated to advancing their health equity agendas. 
March 15, 2022

Accenture and Microsoft to Assist Mt. Sinai Health System on Five-Year Transformation Journey to Cloud

NEW YORK; March 1, 2022 – Accenture (NYSE: ACN) and Microsoft (NYSE: MSFT) will assist the Mount Sinai Health System (Mount Sinai) with its transition to the cloud to help enable innovation at a much faster pace. By modernizing its infrastructure, Mount Sinai will be able to reinvest cost-savings and focus on its healthcare mission.
March 01, 2022